FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
Season 9, Episode 2, Jun 12, 2023, 06:00 PM
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.